Clinical Research Centre
Institut Kanser Negara
Putrajaya
WhoWe Are
Clinical Research Centre Institut Kanser Negara (CRC IKN) was formally established on 30th October 2014 with the function to coordinate and monitor research activities conducted within IKN premises. Various research-related activities, trainings and consultations have been held every year continuously to promote research activities and to create a good and ethical research foundation among IKN researchers.
OurTeam
InvestigatorsHighlight
Head of CRC, Clinical Oncologist and Deputy Head of Department of Radiotherapy and Oncology, IKN
Email: florencefui@yahoo.com
MCO (UM), MBBS (UM)
Areas of interest: Lung cancer, Hepatobiliary cancer, Genitourinary cancer, Head and neck cancer, Neuroendocrine cancer
Awards and achievements:
- Top Recruiter for RAINBOW and PARACHUTE Trials, 2018
- Clinical Trial Site of the Year, 2018
- Lead Trainer for Master of Clinical Oncology Program in IKN
- Member of Specialty Subcommittee for Education (SSC-Edu) for Clinical Oncology, Medical Education Committee (MEC), Majlis Perubatan Malaysia (MPM)
- External Reviewer for Traditional and Complementary Medicine Practice Guideline on Herbal Therapy as Adjunct Treatment for Cancer Edition 2, 2018
- Member of Clinical Practice Guideline for Nasopharyngeal Carcinoma (Malaysia) Development Group, 2017
- Expert Committee for the Effect of Chinese Herbal Medicine as an Adjunct Management of Fatigue and Muscle Weakness in Cancer Patients Receiving Chemotherapy under Health Technology Assessment, 2017
Dr. Wong Yoke Fui is a distinguished clinical oncologist with over a decade of experience in the field. She currently serves as the Deputy Head of the Radiotherapy and Oncology Department at Institut Kanser Negara (IKN) and has led the Clinical Research Centre (CRC) IKN since 2016. Dr. Wong earned her MBBS degree from Universiti Malaya in 2005 and completed her Master of Clinical Oncology at the same institution in 2014. She is also the Lead Trainer for the Master in Clinical Oncology program at IKN. Since joining IKN in 2014, Dr. Wong has been actively engaged in both Industry Sponsored Research (ISR) and Investigator Initiated Research (IIR), alongside her clinical duties. Her research primarily focuses on solid tumours, with a special interest in head and neck cancers and neuroendocrine tumours. Over the past eight years, Dr. Wong has significantly contributed to oncology trials, serving as Principal Investigator in 22 clinical trials and as Sub-Investigator in an additional 10 trials across various cancer types. Her exceptional dedication to advancing cancer research and improving patient outcomes has earned her the respect and admiration of both colleagues and patients
Research Highlights
Multicentre Clinical Epidemiological Study of Female Breast Cancer in a Multi-ethnic Malaysian Setting (Epi-Can)
Epi-Can is a multicentre retrospective cohort study that involves seven of the Ministry of Health (MOH) hospitals in Malaysia. This study aimed to determine the nature of breast cancer patients’ presentation, diagnosis, management of treatment, treatment-induced cardiovascular complications and survival while describing the variation across age, socioeconomic, geographic regions, ethnic differences and its trend over time in Malaysia. The results of this study will aid in observing secular changes as well as long-term outcomes for breast cancer patients in real-world clinical practice.
Recent Publications
Project Highlights
Multicentre Clinical Epidemiological Study of Female Breast Cancer in a Multi-ethnic Malaysian Setting (Epi-Can)
NMRR ID-22-01338-NBF
Epi-Can is a multicentre retrospective cohort study that involves seven of the Ministry of Health (MOH) hospitals in Malaysia. This study aimed to determine the nature of breast cancer patients’ presentation, diagnosis, management of treatment, treatment-induced cardiovascular complications and survival while describing the variation across age, socioeconomic, geographic regions, ethnic differences and its trend over time in Malaysia. The results of this study will aid in observing secular changes as well as long-term outcomes for breast cancer patients in real-world clinical practice.
Contact: Shridevi Subramaniam
shridevi@crc.gov.my
| NMRR-22-01338-NBF | Multicentre Retrospective Clinical Epidemiological Study Of Female Breast Cancer In A Multi-Ethnic Malaysian Setting (EPI-CAN) |
| NMRR-21-1587-60545 | Marker Assisted Selective Therapy In Rare Cancers: Knowledge Database Establishing Registry Protocol (MASTERKEY) |
| NMRR-21-1588-60115 | Asian Multicenter Prospective Study Of Circulating Tumour DNA Sequencing: A-TRAIN Cervical Cancer Project |
| NMRR-19-1566-48532 | An open label, single arm, multicentre study to assess the clinical efficacy and safety of lynparza (Olaparib) tablets maintenance monotherapy in platinum sensitive relapsed ovarian cancer patients who are in complete or partial re-sponse following platinum based chemotherapy (L-MOCA) |
| NMRR-16-76-28880 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy |
| NMRR-19-1782-49278 | A phase 3 randomized, double blind study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma (MK-3475-966) |
| NMRR-18-3256-44987 | A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naive, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007) |
| NMRR-19-72-46351 | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) |
| NMRR-20-1731-55808 | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPItello-290) |
| NMRR-20-3081-57424 | A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4) |
| NMRR-20-1273-54343 | Phase 3 Randomized, Double-Blind, Phase 3 Study of Platinum-based chemotherapy with or without INCMGA0012-304 in first line metastatic squamous and non-squamous NSCLC (PODIUM-304) |
| NMRR-20-2330-56789 | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-012) |
| NMRR-21-959-58876 | A phase III, open-label, randomized study of atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone in hepatocellular carcinoma previously treated with atezolizumab and bevacizumab (IMbrave) |
| NMRR-21-1587-60545 | A prospective clinical registry study of genetic profiling and targeted therapies in patients with rare cancers in ASIA (Marker Assisted Selective Therapy in Rare cancers: Knowledge database Establishing registry Protocol) (MASTER KEY ASIA) |
| NMRR-23-03126-GYV | A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma (ZINNIA) |
| NMRR-22-00597-U2F | A Study of PembrolIzumab (MK-3475) Plus Platinum and GEmcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) |
| NMRR-21-01967-57N | A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03) |
| NMRR-21-1588-60115 | Asian multicenter prospective study of circulating tumor DNA sequencing: A-TRAIN Cervical Cancer Project protocol (A-TRAIN 01) |
| NMRR-22-00253-9AS | A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA) (HERIZON-GEA-01) |
| NMRR-22-02084-BSI | Asian multicenter prospective study of circulating tumor DNA sequencing: A-TRAIN Ovarian Cancer Project protocol (A-TRAIN 04) |
| NMRR-23-01233-Q9T | A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting (VERBENA) |
| NMRR-23-01237-HVF | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma |
| NMRR-23-02720-YHF | A Randomized, Open-Label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non Small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations (MK-2870-004) |
| NMRR-23-03196-DT2 | A randomized, double-blind, parallel-group study to compare pharmacokinetics of GME751 (proposed pembrolizumab biosimilar) and US-licensed and EUauthorized Keytruda® in participants with stage II and III melanoma requiring adjuvant treatment with pembrolizumab (CGME MELANOMA) |
| NMRR-23-02852-EHQ | A Phase I/III Study of Capivarsertib Plus Palbociclib and Fulvestrant Versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2- Negative Locally Advanced, Unresectable, or Metastatic Breast Cancer (CAPItello-292) |
| NMRR-23-03052-TQK | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato‑DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple‑Negative or Hormone Receptor‑low/HER2-negative Breast Cancer (TROPION‑Breast04) |
| NMRR-23-03248-ADQ | A study to compare efficacy, safety, and immunogenicity of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic nonsquamous non-small cell lung cancer (NSCLC) (SANDOZ) |
| NMRR-23-03052-TQK | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato‑DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple‑Negative or Hormone Receptor‑low/HER2-negative Breast Cancer (TROPION‑Breast04) |
| NMRR-23-03315-JDS | AP063-003: A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of AP063 to Herceptin® in Subjects with HER2+ Breast Cancer (APRILLIAH) |
| NMRR-24-01061-PE0 | A Randomized Phase 3 Study of MK-2870 plus Platinum vs. MK-2870 vs. Platinum Doublets in EGFR-mutated, Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) |
| NMRR-24-01063-NW7 | A randomized, double-blind, parallel-group study to compare pharmacokinetics, efficacy, safety, and immunogenicity of JPB898 (proposed nivolumab biosimilar) and US-licensed and EU-authorized Opdivo® in combination with Yervoy® in participants with untreated advanced (unresectable/metastatic) melanoma (SANDOZ) |
| NMRR-24-00815-PMH | A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-015) |
| NMRR-23-03349-8MF | A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) |
| NMRR-24-00348-COS | A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (V940-002) |
List of Publications associated with CRC IKN
- Survival Analysis of Endometrium Cancer Patients From Three Main Cancer Referral Centres in Malaysia
- Mohd Anuar Siti Fatimah Zahra, Subramaniam Shridevi, Wong Yoke Fui, Abdul Malik Rozita, Yehgambaram Prathepamalar
Services at CRC Institut Kanser Negara
CRC IKN conducts Clinical Research & Trials
- Conduct research according to the MOH priority areas.
- Conduct and provide technical support for clinical trials conducted in IKN.
- Ensure ethical clearance for all research to be carried out in IKN.
Meet Our Collaborators
CRC Institut Kanser Negara
Main Phone: +603-8892 5555 ext 4168
Email: crc.ikn@gmail.com
